The BET Inhibitor GS-5829 Targets Chronic Lymphocytic Leukemia Cells and Their Supportive Microenvironment

Despite major improvements in treatment outcome with novel targeted therapies, such as the Bruton tyrosine kinase (BTK) inhibitor ibrutinib, chronic lymphocytic leukemia (CLL) remains incurable in the majority of patients. Activation of PI3K, NF-κB, and/or MYC has been linked to residual disease and...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Leukemia
Päätekijät: Kim, Ekaterina, ten Hacken, Elisa, Sivina, Mariela, Clarke, Astrid, Thompson, Philip A., Jain, Nitin, Ferrajoli, Alessandra, Estrov, Zeev, Keating, Michael J., Wierda, William G., Bhalla, Kapil N., Burger, Jan A.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: 2019
Aiheet:
Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC7272263/
https://ncbi.nlm.nih.gov/pubmed/31862959
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41375-019-0682-7
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia